HIKAL LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 1,943 | 2,023 | 1,785 | 1,860 | 1,713 |
| EBITDA (ex other income) | 341 | 257 | 267 | 328 | 135 |
| margin % | 17.5 | 12.7 | 15.0 | 17.7 | 7.9 |
| Owners' profit | 0 | 78 | 0 | 0 | (49) |
| EPS, as reported (₹) | 13.02 | 6.36 | 5.64 | 7.36 | (3.96) |
| ROE % · ROCE % | 15.0 · 17.3 | 6.9 · 8.9 | 5.9 · 8.8 | 7.2 · 11.4 | (4.1) · (1.0) |
| Debt / equity (x) | 0.63 | 0.66 | 0.69 | 0.60 | 0.57 |
| Cash from operations | 294 | 315 | 187 | 280 | 302 |
| Capex | (273) | (303) | (204) | (137) | (148) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 453 | 448 | 552 | 380 | 319 | 494 | 519 | 403 |
| Profit before tax | 25 | 24 | 68 | (30) | (47) | (9) | 8 | (10) |
| Net profit | 18 | 17 | 50 | (22) | (35) | (6) | 14 | (7) |
| EPS (₹) | 1.48 | 1.39 | 4.07 | (1.82) | (2.83) | (0.48) | 1.17 | (0.60) |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Pharmaceuticals | 1,021 | 59.6 |
| Crop Protection | 535 | 31.2 |
| Crop protection | 157 | 9.2 |
| Total, before eliminations | 1,713 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 2 Sept 2026 · Hikal schedules analyst and investor meeting on Sep 4 in Pune | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Hikal 38th AGM scheduled for Sept 23, 2026 via video conferencing | compliance | minimal | — | — |
| 31 Aug 2026 · Hikal Limited: 38th AGM notice on Sep 23, 2026; Annual Report FY26 weblink | compliance | minimal | — | — |
| 31 Aug 2026 · Hikal files Business Responsibility and Sustainability Report for FY 2025-26 | compliance | medium | — | — |
| 31 Aug 2026 · Hikal files FY2025-26 Annual Report and 38th AGM notice | board shareholder meetings | low | — | — |
| 31 Aug 2026 · Notice of 38th AGM on Sep 23, 2026; final dividend, director appointments | board shareholder meetings | low | — | — |
| 27 Aug 2026 · TDS communication on final dividend for FY 2025-26 shareholders update | compliance | minimal | — | — |
| 27 Aug 2026 · Hikal sets September 23 AGM and proposes Rs 0.40 final dividend | compliance | minimal | — | — |
| 26 Aug 2026 · Hikal fixes Sept 23, 2026 for 38th AGM; Sept 4 record date for final dividend | board shareholder meetings | low | — | — |
| 26 Aug 2026 · Sameer Hiremath appointed Chairman and Managing Director for 5 years | management changes | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| DIVI S LABORATORIES LTD |
| 2,47,033 |
| 84.6 |
| 14.74 |
| 63.7 |
| 15.3 |
| 18.8 |
| 8.7 |
| 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 2.3 | 3.3 | 60 of 163 | 63% |
| ROCE | (4.6) | 10.8 | 162 of 183 | 12% |
| ROE | (4.1) | 10.4 | 154 of 171 | 10% |
| Debt / Equity | 0.6 | 0.1 | 146 of 171 | 15% |
| EBITDA margin | 11.8 | 17.5 | 110 of 165 | 34% |
| Revenue growth | 5.9 | 16.3 | 109 of 161 | 33% |
| Profit growth | 67.0 | 30.9 | 51 of 158 | 68% |
| Market cap | 2803 | 839 | 69 of 182 | 62% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
